FILSPARI Sales Jump 120% to $200M as Travere Posts Q3 Results
TVTX has more than doubled off its 52-week low of $22.59.
Summary
FILSPARI net product sales hit $200.2 million in Q3 2026, up 120% year-over-year, driving total net product sales to $220.2 million from $113.2 million a year earlier. That is a sharp acceleration from the $141.1 million reported in Q2, and the FSGS launch is contributing with 1,932 new patient start forms in the quarter. The quarter still showed a GAAP net loss of $52.3 million, or $0.55 per share, largely because of a $113.1 million IPR&D charge tied to closing the Everest Medicines civorebrutinib licensing deal; on a non-GAAP basis the loss was $29.6 million, or $0.31 per share. Cash and marketable securities stood at $471.8 million at quarter-end, with convertible debt of $603.5 million on the balance sheet. The commercial trajectory is the story here, and it lands just ahead of the December 1 CEO handoff to Bradley Campbell. Pegtibatinase Phase 3 HARMONY topline data is guided for the second half of 2027.
At the time of this announcement, TVTX was trading at $49.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6B. The 52-week trading range was $22.59 to $68.73. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.